Researchers from Zhejiang University and HKUST (Guangzhou) have developed a cutting-edge AI model, ProtET, that leverages multi-modal learning to enable controllable protein editing through text-based instructions.

The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence (AI). Traditionally, drug development has been a lengthy, costly, and uncertain process.

The protein was then synthesized and tested in the lab. It glowed—a clear sign of success. The AI had effectively charted a course through the vast “protein space,” simulating evolutionary processes that might take nature hundreds of millions of years to accomplish.

CES 2025, the largest tech event in the world, welcomed over 141,000 attendees from around the globe – eager to share and learn about the latest consumer technology innovations.

A new ML-guided platform can design thousands of new enzymes, predict how they will behave in the real world, and test their performance.

In a paper published in Nature Biotechnology, three Stanford University-affiliated co-authors, including Stanford Law School Professor Lisa Larrimore Ouellette, tackle an issue of growing importance at the intersection of law and technology: How the use of artificial intelligence to codify and communicate knowledge may influence the usefulness of the technical literature for subsequent researchers and innovators.

YZi Labs announced it changed its company name from Binance Labs to operate independently. The firm will expand its investment focus beyond crypto and blockchain to include Artificial Intelligence (AI) and biotechnology (biotech).

The biotech scene can be seen as fairly risky for new investors who want to put money to work. After all, it’s really tough to gauge which innovative biotech firms will have something genuinely ground-breaking to come out of their pipelines.

As the Doomsday Clock ticks dangerously close to midnight, humanity faces escalating nuclear threats, climate disasters, and tech-driven risks.

President Trump has inherited an evolving chemical and biological threat landscape, but not one he hasn’t encountered before. Trump struck Bashar al-Assad’s airbases in 2017 and 2018, after the

India needs to grow at 8 percent for up to two decades to become a developed nation by 2047, the Economic Survey said on Friday, pitching for a slew

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular immunotherapies for cancer and immune disorders.